Article

Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial

2022-05-03

Abstract excerpt

Background: A booster dose of COVID-19 vaccine is required to prolong immune persistence and strengthen the protection against variants. Therefore, we assessed the safety and immunogenicity of homologous boosting with an inactivated vaccine (CoronaVac), as well as the cross-neutralising activity against the Omicron variant in children and adolescents aged 3-17 years.<br><br>Methods: In the phase 2 clinical trial,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 95beaa08-4d8e-5fe8-92a6-2622312e636d
DOI: 10.2139/ssrn.4099431

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical TrialDOI 10.2139/ssrn.4099431Read

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read

Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy AdolescentsSemantic proximity Read

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in BrazilSemantic proximity Read

Post-vaccination T cell immunity to omicronSemantic proximity Read

Vaccine effectiveness of CoronaVac against symptomatic and severe COVID-19 among children in Brazil during the Omicron periodSemantic proximity Read

Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic reviewSemantic proximity Read

The BTN162b2 Vaccine Induces Humoral and Cellular Immune Memory to Wuhan Strain SARS-CoV-2 and the Omicron Variant in Children 5 to 11 Years of AgeSemantic proximity Read

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trialSemantic proximity Read

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity Read

Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United StatesSemantic proximity Read